Category Group:
Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company has opened clinical trial enrollment for CM-AT, its autism treatment, at the University of Pittsburgh and the Alexian Brothers Behavioral Health Hospital in Hoffman Estates, Illinois, near Chicago. A total of 12 sites nationwide are recruiting patients for CM-AT Phase III clinical trials.
CM-AT is based on Curemark's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. CM-AT has received Fast Track status from the FDA. If approved, it will be one of the first therapies to address the underlying physiology of autism.
"Curemark's clinical trial program is making rapid progress, with enrollment moving forward quickly at our CM-AT trial sites," said Dr. Joan Fallon, Curemark founder and CEO. "We're also considering additional sites with potential interest in participating in the CM-AT clinical research."
For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com
Safe Harbor Statement - This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.